Zhang Nian-Zhang, Wang Meng, Xu Ying, Petersen Eskild, Zhu Xing-Quan
a State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute , Chinese Academy of Agricultural Sciences , Lanzhou , PR China.
b Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, National Animal Protozoa Laboratory, College of Veterinary Medicine , China Agricultural University , Beijing , PR China.
Expert Rev Vaccines. 2015;14(12):1609-21. doi: 10.1586/14760584.2015.1098539. Epub 2015 Oct 14.
Toxoplasma gondii, a significant public health risk, is able to infect almost all warm-blooded animals including humans, and it results in economic losses in production animals. In the last three years, a large number of vaccination experiments have been performed to control T. gondii infection, with the target of limiting the acute infection and reducing or eliminating tissue cysts in the intermediate hosts. In this paper, we summarize the latest results of the veterinary vaccines against T. gondii infection since 2013. Immunization with live-attenuated whole organisms of non-reverting mutants has been shown to induce remarkably potent immune responses associated with control of acute and chronic toxoplasmosis. The non-cyst-forming mutants are promising new tools for the development of veterinary vaccines against T. gondii infection.
弓形虫是一种重大的公共卫生风险因素,能够感染包括人类在内的几乎所有温血动物,并给生产动物带来经济损失。在过去三年中,人们进行了大量疫苗接种实验以控制弓形虫感染,目标是限制急性感染并减少或消除中间宿主中的组织包囊。在本文中,我们总结了自2013年以来针对弓形虫感染的兽用疫苗的最新研究成果。使用非回复突变体的减毒活全生物体进行免疫已被证明可诱导与控制急性和慢性弓形虫病相关的显著有效的免疫反应。非形成包囊的突变体是开发抗弓形虫感染兽用疫苗的有前景的新工具。